JP Morgan Maintains Overweight on Relay Therapeutics, Lowers Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph maintains an Overweight rating on Relay Therapeutics but lowers the price target from $23 to $21.
September 10, 2024 | 2:58 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan's analyst Eric Joseph continues to rate Relay Therapeutics as Overweight, indicating a positive outlook, but has adjusted the price target downwards from $23 to $21.
The Overweight rating suggests a positive outlook for Relay Therapeutics, but the lowered price target indicates some tempered expectations. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100